Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
Adults with T2D initiating semaglutide OW in the real-world had significant decreases in weight, BMI, and HbA1c after 1 year, with greater improvements versus SGLT2i, and similar HCRU.
Authors
- Riddhi Doshi (ORCID: https://orcid.org/0000-0002-1439-1511)
- JAMES AMAMOO
- Mico Guevarra (ORCID: https://orcid.org/0009-0001-9381-4411)
- Cory Gamble (ORCID: https://orcid.org/0000-0001-9343-4761)
- Aaron A. King (ORCID: https://orcid.org/0000-0001-6159-3207)
- Victoria Divino (ORCID: https://orcid.org/0000-0001-5555-7912)
- Lin Xie (ORCID: https://orcid.org/0000-0003-3006-5537)
- Joshua Noone
- Justin Chen (ORCID: https://orcid.org/0009-0002-7960-9697)
Institutions
- Novo Nordisk (United States) (US)
- IQVIA (United States) (US)
- Primary Health Care (QA)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1007/s13300-025-01721-y
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29